- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07608458
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
Scheduled Meditation for Perioperative Optimization: A Randomized Controlled Trial on Postoperative Outcomes, Pain, Anxiety, Insomnia, Stress, and Mobility in Pancreatectomy Patients
Studienübersicht
Status
Detaillierte Beschreibung
PRIMARY OBJECTIVES:
I. Evaluate the feasibility of implementing a meditation-based intervention in patients undergoing pancreatectomy, as measured by recruitment, retention, and participant compliance with the prescribed modules II. Evaluate the effect of a perioperative meditation intervention on anxiety, as measured by changes in State-Trait Anxiety Inventory (STAI) scores from baseline to one month postoperatively.
SECONDARY OBJECTIVE:
I. To observe the relationship of meditation intervention on change in health-related quality of life (HRQOL) outcomes for pain and sleep quality from baseline through one month postoperatively.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive access to the Headspace application. Patients complete mindfulness meditation including focused breathing, awareness of thought patterns, and management of mind-wandering for 10 minutes once daily (QD) for 3 weeks prior to surgery and twice daily (BID) for 1 month after surgery. Patients wear a Garmin activity tracker throughout the study.
ARM II: Patients receive access to the Headspace application at the time of hospital discharge and will be informed of the availability of the "Basics" meditation pack. Patients wear a Garmin activity tracker throughout the study.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
California
-
Duarte, California, Vereinigte Staaten, 91010
- City of Hope Medical Center
-
Kontakt:
- Bradford Kim
- Telefonnummer: 626-218-1840
- E-Mail: brakim@coh.org
-
Hauptermittler:
- Bradford Kim
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Documented informed consent of the participant and/or legally authorized representative
- Willing to install required apps on personal smartphone
- Willing to wear a Garmin wearable device throughout the study
- Age: ≥ 18 years
- Ability to read and understand English for questionnaires
- Owns a smartphone
- Comfortable with routine smartphone use
- Scheduled to undergo pancreatectomy
Exclusion Criteria:
- Participants with prior formal training in meditation or mindfulness (e.g., completion of structured courses, workshops, or certification programs)
- Participants who currently engage in a structured meditation or mindfulness practice, including regular use of mobile applications (e.g., Headspace, Calm, or similar platforms) or other formalized routines
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Arm I (Headspace meditation)
Patients receive access to the Headspace application.
Patients complete mindfulness meditation including focused breathing, awareness of thought patterns, and management of mind-wandering, for 10 minutes QD for 3 weeks prior to surgery and BID for 1 month after surgery.
Patients wear a Garmin activity tracker throughout the study.
|
Nebenstudien
Wear activity tracker
Complete mindfulness mediation
Andere Namen:
Receive access to Headspace
Andere Namen:
|
|
Experimental: Arm II (Delayed access to Headspace)
Patients receive access to the Headspace application at the time of hospital discharge and will be informed of the availability of the "Basics" meditation pack.
Patients wear a Garmin activity tracker throughout the study.
|
Nebenstudien
Wear activity tracker
Complete mindfulness mediation
Andere Namen:
Receive access to Headspace
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Proportion of enrolled patients who complete the final study assessment (retention)
Zeitfenster: Up to 6 months
|
Retention will be considered feasible if ≥ 70% of enrolled participants are retained.
Will be estimated along with the 95% exact binomial confidence interval.
|
Up to 6 months
|
|
Proportion of prescribed meditation modules completed (compliance)
Zeitfenster: Up to 6 months
|
Each participant's proportion of completed meditation modules will be calculated using usage data from the Headspace mobile application.
Participants will then be classified as high (> 60%), medium (20-60%), or low (< 20%) compliance.
Will be estimated along with the 95% exact binomial confidence interval.
|
Up to 6 months
|
|
Change in patient-reported anxiety symptoms
Zeitfenster: From baseline up to day 28
|
Measured using the State-Trait Anxiety Inventory (STAI).
Response is defined as a reduction of at least 6 points on STAI at date of surgery date relative to baseline.
The proportion of participants meeting this threshold will be reported.
Will be estimated along with the 95% exact binomial confidence interval.
Within-group mean change in STAI will be examined using paired t-tests (comparing any two time points of interest).
|
From baseline up to day 28
|
|
Proportion of invited patients who agree to participate (recruitment)
Zeitfenster: Up to 6 months
|
Recruitment will be considered feasible if ≥ 50% of eligible patients enroll.
Will be estimated along with the 95% exact binomial confidence interval.
|
Up to 6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in patient-reported pain - Numeric Rating Scale
Zeitfenster: rom the baseline assessment conducted three weeks prior to surgery through one month after surgery.
|
Change in patient-reported pain from baseline three weeks prior to surgery through one month postoperatively, measured using the Numeric Rating Scale (NRS, 0 -10 ).
0 means no pain to 10 means worst pain possible.
|
rom the baseline assessment conducted three weeks prior to surgery through one month after surgery.
|
|
Change in patient-reported pain - Brief Pain Inventory
Zeitfenster: From the baseline assessment conducted three weeks prior to surgery up to one month after surgery.
|
Change in patient-reported pain from baseline three weeks prior to surgery through one month postoperatively, measured using the Brief Pain Inventory.(BPI).
0 means no pain to 10 means worst pain possible.
|
From the baseline assessment conducted three weeks prior to surgery up to one month after surgery.
|
|
Change in patient-reported Pittsburgh Sleep Quality Index (PSQI)
Zeitfenster: From baseline up to one month after surgery.
|
Self-reported questionnaire will be used to measure sleep quality and sleep patterns over the past month.
PSQI will be interpreted by totaling the component scores into a global score ranging from 0 to 21, where higher scores indicate poorer sleep quality; a score greater than 5 generally suggests significant sleep disturbance or poor sleep quality.
|
From baseline up to one month after surgery.
|
|
Change in patient-reported Insomnia Severity Index (ISI)
Zeitfenster: From baseline up to one month after surgery.
|
Self-reported questionnaire will be used to assess the severity and impact of insomnia symptoms, including difficulty falling asleep, staying asleep, and the effect of sleep problems on daily functioning.
The ISI is interpreted using a total score from 0 to 28: 0-7 indicates no clinically significant insomnia, 8-14 indicates subthreshold insomnia, 15-21 indicates moderate insomnia, and 22-28 indicates severe insomnia.
|
From baseline up to one month after surgery.
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Ermittler
- Hauptermittler: Bradford Kim, City of Hope Medical Center
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Neubildungen nach Standort
- Neubildungen
- Neubildungen nach histologischem Typ
- Neoplasmen des Verdauungssystems
- Erkrankungen des Verdauungssystems
- Neoplasmen der endokrinen Drüse
- Erkrankungen der Bauchspeicheldrüse
- Erkrankungen der Gallenwege
- Leberkrankheiten
- Neubildungen, Drüsen und Epithelien
- Adenokarzinom
- Lebertumoren
- Karzinom
- Neoplasien der Gallenwege
- Karzinom, hepatozellulär
- Neoplasmen der Bauchspeicheldrüse
- Untersuchungstechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Überwachung, physiologisch
- Beschleunigung
- Actigraphie
Andere Studien-ID-Nummern
- 25479 (Andere Kennung: City of Hope Medical Center)
- P30CA033572 (US NIH Stipendium/Vertrag)
- NCI-2026-03206 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hepatozelluläres Karzinom
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Abgeschlossen
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)BeendetBrustkrebsVereinigte Staaten
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Beth Israel Deaconess Medical Center; Brigham...Aktiv, nicht rekrutierendDuktales Carcinoma in situ der BrustVereinigte Staaten
-
University of AarhusUnbekanntCarcinoma in situ des GebärmutterhalsesDänemark
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; Hamilton Health Sciences CorporationUnbekanntInvasiver Brustkrebs | Duktales Carcinoma in situ der BrustKanada
-
University of Southern CaliforniaBeendetBrustkrebsVereinigte Staaten
-
Endo PharmaceuticalsAbgeschlossen
-
Jeong Eon LeeNoch keine RekrutierungDuktales Carcinoma in situ der BrustSüdkorea
-
Fujian Provincial HospitalRekrutierungCarcinoma in situ des zervikalen Teils der SpeiseröhreChina
-
Danish Breast Cancer Cooperative GroupDanish Cancer SocietyAktiv, nicht rekrutierendBrustkrebs | Carcinoma in situ der BrustDänemark
Klinische Studien zur Umfrageverwaltung
-
Children's Mercy Hospital Kansas CityRekrutierungDiabetes mellitus Typ 1Vereinigte Staaten
-
Virginia Commonwealth UniversityRigel PharmaceuticalsRekrutierungAkute myeloische LeukämieVereinigte Staaten
-
Centre for Research and Technology HellasRekrutierungMyelodysplastische Syndrome | Chronischer lymphatischer LeukämieItalien
-
Catholic University of the Sacred HeartAbgeschlossenLebensqualität | Chirurgische Wunde | Biopsie-Wunde | Heilung von OperationswundenItalien
-
Daewoong Pharmaceutical Co. LTD.AbgeschlossenGesundKorea, Republik von
-
Daewoong Pharmaceutical Co. LTD.Unbekannt
-
Daewoong Pharmaceutical Co. LTD.AbgeschlossenStudie zur Arzneimittelinteraktion zwischen DWC20155/DWC20156 und DWC20161 bei gesunden FreiwilligenGesundKorea, Republik von
-
University of ChicagoNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...AbgeschlossenDiabetes mellitus, Typ 2Vereinigte Staaten
-
Abramson Cancer Center at Penn MedicineAnmeldung auf EinladungOnkologieVereinigte Staaten
-
Fondazione Poliambulanza Istituto OspedalieroUnbekanntMedikationsfehler und andere Fehler und Probleme bei der Produktverwendung | Unerwünschtes ArzneimittelereignisItalien